Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.
Immune responses to meningococcal conjugate (Menactra; MCV-4) and plain polysaccharide (Menomune-A/C/Y/W-135; PSV-4) vaccines against serogroups A, C, Y, and W-135 were assessed in 220 of 1037 Chilean children aged 2 to 10 years participating in a comparative safety trial. Both vaccines were generally well tolerated. Geometric mean serum bactericidal antibody (SBA) titers 28 days postvaccination were comparable in both groups for all four serogroups. Seroconversion was evident in > 97% of MCV-4 and > 90% of PSV-4 vaccinees who tested seronegative at baseline. Menactra safely induced broad and robust immune responses against serogroups A, C, Y and W-135 in this population.
Lagos
Rosanna
R
Centro para Vacunas en Desarrollo, Santiago, Chile. rlagos@adsl.tie.d
Papa
Thomas
T
Muñoz
Alma
A
Ryall
Robert
R
Pina
Miriam
M
Bassily
Ehab
E
D002648:Child; D002675:Child, Preschool; D002677:Chile / Q000453:epidemiology; D004168:Diphtheria Toxoid / Q000009:adverse effects* / Q000276:immunology*; D006262:Health; D006801:Humans; D008589:Meningococcal Infections / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000009:adverse effects* / Q000276:immunology*; D014611:Vaccination; D018074:Vaccines, Conjugate / Q000009:adverse effects* / Q000276:immunology*
D004168:Diphtheria Toxoid; D022401:Meningococcal Vaccines; D018074:Vaccines, Conjugate